Table 6.
Relationship between inflammatory indexes and recurrence in patients with stage IIB cervical cancer.
| Inflammatory indexes | Recurrence (%) | OR (95% CI) | P value |
|---|---|---|---|
| PLR | |||
| <154.17 | 25.3 | 1 (reference) | |
| ≥154.17 | 27.8 | 1.103 (0.635–1.912) | 0.729 |
| NLR | |||
| <2.49 | 19.8 | 1 (reference) | |
| ≥2.49 | 30.5 | 1.704 (0.913–3.185) | 0.046 |
| MLR | |||
| <0.26 | 19.8 | 1 (reference) | |
| ≥0.26 | 37.2 | 2.392 (1.370–4.184) | 0.002 |
| BLR | |||
| <0.021 | 27.7 | 1 (reference) | |
| ≥0.021 | 28.5 | 1.017 (0.592–1.745) | 0.952 |
| SIRI | |||
| <1.02 | 23.1 | 1 (reference) | |
| ≥1.02 | 31.9 | 1.536 (0.885–2.667) | 0.126 |
PLR, platelet-to-lymphocyte ratio; NLR, neutrophil-to-lymphocyte ratio; MLR, monocyte-to-lymphocyte ratio; BLR, basophil-to-lymphocyte ratio; SIRI, systemic inflammation response index; OR, odds ratio; CI, confidence interval.